Core Laboratories INC. /De/ (CLB) — SEC Filings

Overview

Core Laboratories INC. /De/ (CLB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 7, 2026: On April 1, 2026, Robert Klingensmith Harvey, a reporting person for Core Laboratories Inc. /DE/, reported a change in beneficial ownership of securities. The filing details transactions related to his holdings, but specific details on the nature or value of these transactions are not provided in th

Sentiment Summary

Across 32 filings, the sentiment breakdown is: 1 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Core Laboratories INC. /De/ is neutral.

Filing Type Overview

Core Laboratories INC. /De/ (CLB) has filed 6 4, 12 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 1 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (32)

• 4 Filing — 4 · Apr 8, 2026
• 4 Filing — 4 · Apr 7, 2026
• Core Laboratories Inc. Insider Ownership Update — 4 · Apr 7, 2026 Risk: low
  On April 1, 2026, Robert Klingensmith Harvey, a reporting person for Core Laboratories Inc. /DE/, reported a change in beneficial ownership of securities. The f
• 4 Filing — 4 · Apr 7, 2026
• Core Laboratories Inc. Insider Ownership Change Reported — 4 · Apr 7, 2026 Risk: low
  On April 1, 2026, Robert F. Martinovich reported a change in beneficial ownership of securities for Core Laboratories Inc. /DE/. The filing details transactions
• Core Laboratories Inc. Insider Ownership Change Reported — 4 · Apr 7, 2026 Risk: low
  On April 1, 2026, Martha Z. Carnes, a reporting person associated with Core Laboratories Inc. /DE/, reported a change in beneficial ownership of securities. The
• Core Labs Files 8-K: Regulation FD Disclosure on March 23, 2026 — 8-K · Mar 23, 2026
  Core Laboratories Inc. /DE/ filed an 8-K on March 23, 2026, under Item 7.01, Regulation FD Disclosure. This filing indicates that the company is providing infor
• Core Lab's Q3 Net Income Jumps Amidst Debt Reduction — 10-Q · Oct 23, 2025 Risk: medium
  Core Laboratories Inc. reported a mixed financial performance for the three and nine months ended September 30, 2025. For the three months, total revenue slight
• Core Laboratories Inc. Files 8-K on Financials — 8-K · Oct 22, 2025 Risk: low
  Core Laboratories Inc. /DE/ filed an 8-K on October 22, 2025, reporting on its Results of Operations and Financial Condition, and including Regulation FD Disclo
• Core Lab Swings to Q2 Loss Amid Revenue Dip — 10-Q · Jul 25, 2025 Risk: high
  Core Laboratories Inc. (CLB) reported a net loss of $1.5 million for the second quarter of 2025, a significant decline from a net income of $3.2 million in the
• Core Laboratories Inc. Files 8-K on Financial Obligations — 8-K · Jul 23, 2025 Risk: medium
  On July 22, 2025, Core Laboratories Inc. entered into a material definitive agreement, likely related to its financial obligations. The company also reported on
• Core Laboratories Inc. Files 8-K on Shareholder Matters — 8-K · May 27, 2025 Risk: low
  Core Laboratories Inc. /DE/ filed an 8-K on May 27, 2025, reporting on matters submitted to a vote of security holders as of May 21, 2025. The filing details th
• Core Laboratories Inc. Files Q1 2025 10-Q — 10-Q · Apr 28, 2025 Risk: medium
  Core Laboratories Inc. reported its first quarter 2025 results ending March 31, 2025. The company's filing details its financial performance and operational seg
• Core Laboratories Inc. Files 8-K on Financials — 8-K · Apr 23, 2025 Risk: low
  Core Laboratories Inc. /DE/ filed an 8-K on April 23, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financ
• Core Labs DEF 14A: Executive Pay & 2024 Performance — DEF 14A · Mar 31, 2025 Risk: medium
  Core Laboratories Inc. filed a DEF 14A on March 31, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes inf
• Core Laboratories Files 2024 10-K — 10-K · Feb 13, 2025 Risk: medium
  Core Laboratories Inc. filed its 2024 10-K on February 13, 2025, reporting on its fiscal year ending December 31, 2024. The company, based in Houston, TX, opera
• Core Laboratories Inc. Files 8-K on Financials — 8-K · Jan 29, 2025 Risk: low
  Core Laboratories Inc. /DE/ filed an 8-K on January 29, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Fina
• Core Laboratories Inc. Files Q3 2024 10-Q Report — 10-Q · Oct 24, 2024 Risk: medium
  Core Laboratories Inc. reported its third-quarter results for the period ending September 30, 2024. The company's filing indicates financial activities and disc
• Core Laboratories to be Acquired for $1.4B — 8-K · Oct 23, 2024 Risk: medium
  Core Laboratories Inc. announced on October 23, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of American Securities LLC.
• Core Laboratories Inc. Files Q2 2024 10-Q — 10-Q · Jul 25, 2024 Risk: medium
  Core Laboratories Inc. /DE/ filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Core Laboratories Inc. Files 8-K on Financials — 8-K · Jul 24, 2024 Risk: low
  Core Laboratories Inc. /DE/ filed an 8-K on July 24, 2024, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financi
• Core Laboratories Inc. Files 8-K on Shareholder Votes — 8-K · May 10, 2024 Risk: low
  Core Laboratories Inc. /DE/ filed an 8-K on May 10, 2024, reporting on matters submitted to a vote of security holders as of May 8, 2024. The filing details the
• Core Laboratories Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · Apr 25, 2024 Risk: medium
  Core Laboratories Inc. /DE/ (CLB) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. Core Laboratories Inc. filed its 10-Q report for the period en
• Core Laboratories Announces Q1 2024 Earnings Release Date — 8-K · Apr 24, 2024 Risk: low
  Core Laboratories Inc. announced on April 24, 2024, that it will be releasing its first quarter 2024 financial results after market close on May 1, 2024. The co
• Core Laboratories Appoints New CFO — 8-K · Mar 25, 2024 Risk: medium
  Core Laboratories Inc. announced on March 21, 2024, the appointment of Christopher J. M. L. van Dyck as Chief Financial Officer, effective March 25, 2024. He wi
• Core Laboratories Inc. Files Definitive Proxy Statement — DEF 14A · Mar 19, 2024 Risk: low
  Core Laboratories Inc. /DE/ (CLB) filed a Proxy Statement (DEF 14A) with the SEC on March 19, 2024. Filing is a Definitive Proxy Statement (DEF 14A) filed on Ma
• Core Laboratories Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 15, 2024 Risk: medium
  Core Laboratories Inc. /DE/ (CLB) filed a Annual Report (10-K) with the SEC on February 15, 2024. Core Laboratories Inc. filed its 10-K report for the fiscal ye
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Core Labs Files 8-K on Financial Condition, Operations — 8-K · Jan 31, 2024
  Core Laboratories Inc. /DE/ filed an 8-K on January 31, 2024, reporting on its results of operations and financial condition. This filing, under SEC File Number
• BlackRock Discloses 5.0% Stake in Core Laboratories — SC 13G · Jan 22, 2024
  BlackRock Inc., a major investment firm, reported on January 22, 2024, that it beneficially owns 5.0% of Core Laboratories Inc. /DE/'s common stock as of Decemb

Risk Profile

Risk Assessment: Of CLB's 23 recent filings, 1 were flagged as high-risk, 11 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Core Laboratories INC. /De/'s most recent 10-Q filing (Oct 23, 2025):

• Revenue: $134.521M
• Net Income: $14.239M
• EPS: $0.31
• Debt-to-Equity: N/A
• Cash Position: $25.629M
• Operating Margin: N/A
• Total Assets: N/A
• Total Debt: $114.103M

Key Executives

• Robert Klingensmith Harvey
• Robert F. Martinovich
• Martha Z. Carnes
• Russia
• Ukraine
• Christopher J. M. L. van Dyck

Industry Context

Core Laboratories operates within the oilfield services sector, which is intrinsically linked to global energy demand and commodity prices. The industry is characterized by cyclicality, technological innovation, and increasing pressure for sustainable practices. Competitors range from large diversified service providers to specialized niche players.

Top Tags

financial-reporting (4) · oil-gas (4) · 10-Q (4) · insider-filing (3) · ownership-change (3) · regulation-fd (3) · oil-gas-services (3) · Core Laboratories (3) · Energy Sector (2) · 8-k (2)

Key Numbers

• Period of Report: 2026-04-01 — Date of reported ownership change
• Filing Date: 2026-04-07 — Date the report was accepted by the SEC
• Total Revenue (Q3 2025): $134.521M — Slight increase from $134.397M in Q3 2024
• Net Income Attributable to CLB (Q3 2025): $14.239M — Increased from $11.745M in Q3 2024
• Total Revenue (YTD Q3 2025): $388.265M — Decreased from $394.611M in YTD Q3 2024
• Net Income Attributable to CLB (YTD Q3 2025): $24.721M — Increased from $23.997M in YTD Q3 2024
• Long-Term Debt (Sept 30, 2025): $114.103M — Decreased from $126.111M at Dec 31, 2024
• Common Stock Repurchases (YTD Q3 2025): $9.770M — Significantly up from $402K in YTD Q3 2024
• Basic EPS Attributable to CLB (Q3 2025): $0.31 — Increased from $0.25 in Q3 2024
• Basic EPS Attributable to CLB (YTD Q3 2025): $0.53 — Increased from $0.51 in YTD Q3 2024
• Cash and Cash Equivalents (Sept 30, 2025): $25.629M — Increased from $19.157M at Dec 31, 2024
• Net Cash Provided by Operating Activities (YTD Q3 2025): $29.085M — Decreased from $35.773M in YTD Q3 2024
• Net Loss: $1.5M — Q2 2025, a swing from $3.2M net income in Q2 2024
• Q2 2025 Revenue: $120.5M — Slight decrease from $122.1M in Q2 2024
• Six-Month Net Loss: $0.8M — For period ended June 30, 2025, compared to $6.5M net income in prior year

Related Companies

SLB · HAL · BKR

Frequently Asked Questions